Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

Fig. 4

Cellular phenotyping of the tumor immune microenvironment (TME). a T Cell infiltration – Total CD3 vs. CTL infiltration in tumor (dark) and stroma (light) (b) Cytotoxic T cell (CTL) activation by tissue location and activation status, HLADR+ active/HLA-DR- inactive. c CD68 distribution by location. d SOX10+ PDL1 expression. Of note, representative tissue images did not include any PDL1+ CD68 cells or PDL1+ tumor (SOX10+) cells

Back to article page